BIOMARKER:

TET2 mutation

Entrez ID:

Related biomarkers:

‹

›

TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Resistant: C2 – Inclusion Criteria
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	cytarabine Sensitive: C2 – Inclusion Criteria
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	azacitidine Sensitive: C2 – Inclusion Criteria
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C2 – Inclusion Criteria
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	quizartinib Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	talazoparib Sensitive: D – Preclinical